1498.HK - PuraPharm Corp Ltd Profile | Reuters

PuraPharm Corporation Ltd is an investment holding company principally engaged in the concentrated Chinese medicine granule (CCMG) businesses. PuraPharmCorpLtd1498.HKLatestTrade0.89HKDChange-0.05(-5.32%)Volume2,667,000Today'sRange0.88 - 0.9552WeekRange0.66 - 1.34AsofontheHongKongStockExchange∙Minimum15minutedelayProfileNewsKeyDevelopmentsChartsPeopleFinancialsKeyMetricsEventsAllListingsPricingPreviousClose0.94Open0.94Volume2,667,0003MAVGVolume29.13Today'sHigh0.95Today'sLow0.8852WeekHigh1.3452WeekLow0.66SharesOut(MIL)394.89MarketCap(MIL)351.45ForwardP/E--Dividend(Yield%)--AdvancedChartingNextEventPuraPharmCorpLtdAnnualShareholdersMeetingLatestDevelopmentsMorePurapharmCorpSaysLauKaKuenHasResignedAsCFOPuraPharmCorpPostsFYProfitAttributableOfHK$31.7MillionPuraPharmFYProfitAttributableHK$31.7Mlnfor-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-upAboutPuraPharmCorpLtdPuraPharmCorporationLtdisaninvestmentholdingcompanyprincipallyengagedintheconcentratedChinesemedicinegranule(CCMG)businesses.TheCompanyoperatesthroughfivebusinesssegments.TheChinaCCMGsegmentismainlyengagedintheproductionandsalesofCCMGproductsinChina.TheHongKongCCMGsegmentismainlyengagedinthesalesofCCMGproducts,excludingthesalesthroughself-operatedclinicsinHongKong.TheChineseHealthcareProductssegmentismainlyengagedintheproductionandsalesofhealthcareproductsinHongKongandChina.TheClinicssegmentismainlyengagedintheprovisionofChinesemedicaldiagnosticservicesandsalesofCCMGproductsthroughself-operatedclinics.ThePlantationsegmentismainlyengagedintheplantationandtradingofrawChineseherbs,andthemanufactureandsaleoftraditionalChinesemedicine(TCM)decoctionpieces.IndustryBiotechnology&DrugsContactInfo+852.null.28401840https://www.purapharm.com/KeyStatsPriceToEarnings(TTM)10.87PriceToSales(TTM)0.56PriceToBook(MRQ)0.67PriceToCashFlow(TTM)4.23TotalDebtToEquity(MRQ)99.74LTDebtToEquity(MRQ)38.62ReturnonInvestment(TTM)4.52ReturnonEquity(TTM)2.49LatestNewsLatestNewsNewStoriesBRIEF-PuraPharmCorpPostsNetLossForYearOfHK$227.3Mln*NETLOSSFORYEARHK$227.3MILLIONVERSUSPROFITOFHK$20.8MILLIONBRIEF-PurapharmCorpSaysGuangxiZhuangAutonomousRegionFDAApprovedApplicationForUnitToManufactureQingFeiPaiDuTangGranule*GUANGXIZHUANGAUTONOMOUSREGIONFDAAPPROVEDAPPLICATIONFORUNITTOPREPARE&MANUFACTUREQINGFEIPAIDUTANGGRANULESourcetextforEikon:Furthercompanycoverage:BRIEF-PurapharmCalrifiesonRumorsRegardingDisruptionAndSuspensionOfProductionFacilities*NOTEDRUMOURSTHATOPERATIONOFCONCENTRATEDCHINESEMEDICINEGRANULEPRODUCTIONFACILITIESINNANNING,HAVEBEENDISRUPTEDANDSUSPENDEDQuoteandfinancialdatafromRefinitiv.FundperformancedataprovidedbyLipper.Allquotesdelayedaminimumof15minutes.for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up